DiscoverOxford+
Oxford+

Oxford+

Author: Susannah de Jager

Subscribed: 1,631Played: 5,705
Share

Description

Welcome to Oxford+, the podcast series that explores the myths and truths of the Oxford investing landscape hosted by Susannah de Jager. Since moving to Oxford, Susannah has collaborated with experts, entrepreneurs, and government to shape the conversation around domestic scale-up capital. Oxford+ aims to inform, inspire, and connect. We'll talk to Founders, investors, academics, politicians, and facilitators and explore how Oxford is open for business.
79 Episodes
Reverse
What would the UK look like if it finally kept the companies it builds? In this Oxford+ in Brief, host Susannah de Jager puts her rapid-fire questions to Dr Hermann Hauser, co-founder of Amadeus Capital Partners and co-founder of Arm, with a UK rather than Oxford lens. His answers are short and unambiguous: more hectocorns built and retained at home, a university and startup system newcomers should plug straight into, and a scale-up stage that remains the country's structural weakness. He wants Britain inside the Scaleup Europe Fund, an ambition with live political context given reports that the UK has put €150 million on the table ahead of a UK and EU summit expected before the end of the year, according to Research Professional News. His magic wand is simpler still: move 1% of Europe's pension assets into technology companies and venture capital. Progress at home is real but slow, with Mansion House Accord signatories reporting £11.1 billion in UK private markets.Hermann Hauser: Dr Hermann Hauser KBE FRS is a technology entrepreneur and venture capitalist. Born in Austria, he holds an MA in Physics from the University of Vienna and a PhD in Physics from the University of Cambridge. He co-founded Acorn Computers, the company behind the BBC Micro, and in 1990 helped spin out Arm, whose chip designs now power most of the world's smartphones. He co-founded Amadeus Capital Partners in 1997 with Anne Glover and is now a Venture Partner there, having founded or invested in companies including Solexa, CSR, Graphcore and Photonic. He is a Fellow of the Royal Society, holds an honorary KBE, and has served on the board of the European Innovation Council and its fund.Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya and HSBC Innovation BankingProduced and Edited by Story Ninety-Four in Oxford.
Why does Europe keep producing breakthrough science and then lose the companies built on it? In this episode of Oxford+, host Susannah de Jager speaks with Dr Hermann Hauser, co-founder of Amadeus Capital Partners and co-founder of Arm, about the gap that has defined European innovation for four decades. Europe creates more startups than the United States and produces university research of comparable quality, yet its scale-ups still cross the Atlantic for the later, larger rounds. Hermann sets out what he believes would change that: a working Scaleup Europe Fund, pension capital permitted to take risk, faster movement of management talent, competitive pay and share options, and a European exchange deep enough to take companies public at home. The fund was formally established in August 2026 with a €5 billion target, and Dutch pension fund ABP has since committed €250 million as the first step of a €1 billion programme. He is candid about Arm itself, naming three costly mistakes, and explains why his forthcoming book argues that sovereignty means the retention of choice. His conclusion is blunt: it's technology, stupid.(00:00) - Welcome to Oxford+ (02:29) - The Hauser Report and the Catapult Network (04:22) - Europe's Biggest Gap: Scale-Ups (05:44) - €15 Trillion in Pension Capital (08:28) - The Mansion House Accord and Trustee Culture (11:51) - Returns, Risk Appetite and Management Talent (14:15) - Ambition and Catching Up with Silicon Valley (15:49) - Technology Sovereignty and the New Book (17:52) - Sovereignty as the Retention of Choice (22:11) - Remuneration, Share Options and Pay (25:27) - The Arm Story: Three Costly Mistakes (29:42) - A European Exchange and Stablecoins Hermann Hauser: Dr Hermann Hauser KBE FRS is a technology entrepreneur and venture capitalist. Born in Austria, he holds an MA in Physics from the University of Vienna and a PhD in Physics from the University of Cambridge. He co-founded Acorn Computers, the company behind the BBC Micro, and in 1990 helped spin out Arm, whose chip designs now power most of the world's smartphones. He co-founded Amadeus Capital Partners in 1997 with Anne Glover and is now a Venture Partner there, having founded or invested in companies including Solexa, CSR, Graphcore and Photonic. He is a Fellow of the Royal Society, holds an honorary KBE, and has served on the board of the European Innovation Council and its fund. He is writing a book on technology sovereignty with Hazem Nakib.Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya and HSBC Innovation Banking.Produced and Edited by Story Ninety-Four in Oxford.
What would healthcare look like if genetics were built into drug discovery and disease prevention? In this Oxford+ in Brief episode, Susannah de Jager puts five quick-fire questions to Sir Peter Donnelly, CEO and co-founder of Genomics. Peter describes a future in which genetic evidence helps researchers develop medicines and select patients, while healthcare systems direct screening and prevention to the people who need them at the right time. He hopes this could lead to more effective medicines and longer, healthier lives. Peter also offers advice to founders entering Oxford: understand the demands, stay close to the mission and choose good colleagues. Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.
Could the same genetic data help us develop better medicines and identify disease risk years before symptoms appear?In this episode of Oxford+ in Partnership with Mishcon de Reya, Susannah de Jager speaks with Sir Peter Donnelly, CEO and co-founder of Genomics, about turning Oxford research into tools for drug discovery and preventative healthcare. Peter explains why assembling public data takes years of careful work, and how human genetics can help scientists choose drug targets and the patients most likely to benefit.The conversation also examines agentic AI, which lets scientists ask questions of genetic data without waiting for specialist analysis. On the healthcare side, Peter describes how polygenic risk scores could guide screening and prevention according to individual risk rather than age alone.Research reported by Exeter on 22 October 2026, drawing on nearly one million genomes, stresses that genetic risk needs clinical and environmental context. That distinction matters as Peter discusses personalised medicine, Our Future Health and the practical challenge of making prevention work within existing healthcare systems.(00:00) - Welcome to Oxford+ (01:14) - From Mathematics to Human Genetics (04:27) - Turning Oxford Research into Genomics (09:10) - Why Combining Genetic Data Is Difficult (13:14) - Using Genetics to Choose Better Drug Targets (17:57) - Choosing Patients and Partnering with Vertex (20:55) - Agentic AI and Access to Genetic Analysis (26:04) - Polygenic Risk Scores and Disease Prevention (29:56) - Personalising Screening and Preventative Care (33:21) - Our Future Health and the NHS (37:15) - International Healthcare Opportunities (39:31) - Growing Genomics and Funding Its Next Steps Sir Peter Donnelly: Professor Sir Peter Donnelly FRS, FMedSci is CEO and co-founder of Genomics and Emeritus Professor of Statistical Science at the University of Oxford. His work applies statistics and probability to human genetics and disease risk. He held leading roles in the International HapMap Project and the Wellcome Trust Case Control Consortium, and previously directed Oxford’s Wellcome Centre for Human Genetics. In 2014, he co-founded Genomics to turn genetic research into tools for drug discovery and disease prevention. He was knighted in 2019 for services to the understanding of human genetics in disease.Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya and HSBC Innovation Banking.Produced and Edited by Story Ninety-Four in Oxford.
What would success look like if Oxford turned more of its scientific discoveries into lasting businesses?In this Oxford+ in Brief episode, Susannah de Jager puts a series of quick-fire questions to Oxford Nanopore co-founder Gordon Sanghera. His answer starts with homegrown companies that remain independent and create jobs and wealth in the UK. He distinguishes independence from ownership, leaving room for overseas investors without abandoning that ambition.Gordon describes an Oxford innovation ecosystem with growing energy, pointing newcomers towards OX Tech Week and the Lamb & Flag. But he also argues that Oxford recognises promising technologies too slowly and should commit investment more quickly when a breakthrough appears credible.Looking towards 2050, Gordon imagines stronger late-stage development support in Oxford, drawing on the Fraunhofer model. His final proposal is more focused collaboration across fragmented research and spin-outs, organised around selected areas where Oxford could build stronger technology businesses.Gordon Sanghera: Dr Gordon Sanghera CBE is the co-founder and former Chief Executive Officer of Oxford Nanopore Technologies. He helped build the business from its formation in 2005 through to its 2021 London Stock Exchange listing. His background combines bioelectronics, product development and manufacturing, including earlier roles at MediSense working on blood glucose testing systems. In October 2026, IP Group confirmed that he had joined Matter Machine, a University of Liverpool spin-out developing AI-powered materials discovery technology, to lead its commercialisation strategy. His experience of turning university research into a commercial business informs his views on Oxford's funding and company-building challenges.Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya and HSBC Innovation Banking.Produced and Edited by Story Ninety-Four in Oxford, UK.
loading
Comments